I think the register has improved considerably in the past 6mths.
We have our Director, Andrew Sparke, controlling the #1 spot when you combine his personal holdings plus his other vehicle, Turkey Investments. In total he owns 3.26%.
James and his wife Neva have also increased their holdings (via issuances and not purchase). They control 2.28% (ex James' interest in GFM).
Then we have the Bond's holdings which are a combined 2.3%.
Kieran Slee, Timora, Norstrom etc aren't selling any so that stock in in good hands.
We've also added Jetosea and Celtic and I'd argue that stock is also safe as these guys have big targets on ARS.
The ones I've highlighted in the image below are the ones that I believe are in safe hands. That adds up to over 19%. Plus my holdings but I wont discuss what they are. Also, this T20 is incomplete because IRESS are morons. There may be other large holders in there that aren't displayed.
![]()
My point is that the register is much better now. There's definitely still overhang and CR participates that want to exit but I really feel like we've soaked much of that volume.
The recent spike up to 2.5 was driven up on really good volume but then the buyers withdrew and it was sold down on very small volumes. That's accumulation.
The stage is set. The register is much tighter. The charts looks like it's ready to break out of a very persistent down trend and we have a retally solid news flow.
We just need the ignition. Who the hell knows what that will be. TF contract execution? Maiden reserves? Deep massive sulfides? JV?
I'm set and ready for whatever comes.
- Forums
- ASX - By Stock
- ARS
- Ann: Mt Ida and Bottle Creek Resource Upgrade Adds 113,000oz Au
Ann: Mt Ida and Bottle Creek Resource Upgrade Adds 113,000oz Au, page-16
-
-
- There are more pages in this discussion • 201 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some